AbbVie Inc.
- Open
- 254.25
- Day high
- 258.24
- Day low
- 252.33
- Prev close
- 255.48
- Volume
- 4.2M
- Mkt cap
- $453.1B
- P/E (TTM)
- 72.2
- EPS (TTM)
- $3.55
- P/B
- -76.3
- P/S
- 7.0
- Yield
- 2.66%
- Per share
- $6.83
- ▼Insiders net selling -$8.2M over the last 3 months (0 open-market buys, 1 sale)
- 🏛Institutions accumulating (13F)
AbbVie Inc. (ABBV) is a Healthcare company listed on NYSE. The stock is up 21% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 1 sale (SEC Form 4). Drillr has 5 published research articles covering ABBV.
AbbVie Inc. (ABBV) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 16 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ABBV earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 31, 2026 | $3.60 | $3.65 | +1.5% | $17.0B | +1.1% |
| Apr 29, 2026 | $2.59 | $2.65 | +2.4% | $15.0B | +2.0% |
| Feb 4, 2026 | $2.63 | $2.71 | +2.8% | $16.6B | +1.3% |
| Oct 31, 2025 | $1.79 | $1.86 | +3.7% | $15.8B | +1.3% |
| Jul 31, 2025 | $2.87 | $2.97 | +3.4% | $15.4B | +2.5% |
| Apr 25, 2025 | $2.38 | $2.46 | +3.4% | $13.3B | +3.2% |
| Jan 31, 2025 | $2.98 | $2.16 | -27.5% | $15.1B | +1.8% |
| Oct 30, 2024 | $2.92 | $3.00 | +2.7% | $14.5B | +1.2% |
| Jul 25, 2024 | $2.57 | $2.65 | +3.1% | $14.5B | +3.1% |
| Apr 26, 2024 | $2.26 | $2.31 | +2.2% | $12.3B | +3.2% |
| Feb 2, 2024 | $2.76 | $2.79 | +1.1% | $14.3B | +10.2% |
| Oct 27, 2023 | $2.86 | $2.95 | +3.1% | $13.9B | +1.9% |
ABBV insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | Donoghoe Nicholasofficer: EVP, CHIEF BUS/STRAT OFFICER | Option | 32,710 | $79.02 |
| Aug 18, 2026 | Donoghoe Nicholasofficer: EVP, CHIEF BUS/STRAT OFFICER | Sell | 32,710 | $250.00 |
| Jul 2, 2026 | Quaggin Susan Edirector | Grant | 62 | $251.64 |
| Jul 2, 2026 | RAPP EDWARD Jdirector | Grant | 134 | $251.64 |
| May 12, 2026 | Davis Jennifer L.director | Grant | 1,118 | — |
| May 12, 2026 | WADDELL FREDERICK Hdirector | Grant | 1,118 | — |
| May 12, 2026 | Hart Brett Jdirector | Grant | 1,118 | — |
| May 12, 2026 | RAPP EDWARD Jdirector | Grant | 1,118 | — |
| May 12, 2026 | AUSTIN ROXANNE Sdirector | Grant | 1,118 | — |
| May 12, 2026 | FALK THOMAS Jdirector | Grant | 1,118 | — |
| May 12, 2026 | MEYER MELODY Bdirector | Grant | 1,118 | — |
| May 12, 2026 | Quaggin Susan Edirector | Grant | 1,118 | — |
| May 12, 2026 | FREYMAN THOMAS Cdirector | Grant | 1,118 | — |
| May 12, 2026 | BURNSIDE WILLIAM H.L.director | Grant | 1,118 | — |
| May 12, 2026 | Roberts Rebecca Bdirector | Grant | 1,118 | — |
Source: ABBV SEC Form 4 filings, latest Aug 18, 2026. For informational purposes only — not investment advice.
See the full ABBV insider & 13F page →ABBV research & analysis
KURA, SNDX: 40% of Menin Inhibitor Use Is Off-Label Combination
Kura and Syndax each report about 40% of menin inhibitor use in physician-led combinations, moving the revenue variable to treatment duration rather than the label.
4503.TKURASNDXSisram (SRAMF), AbbVie (ABBV): Toxin Pricing Shifts to Duration
Sisram, AbbVie and Evolus told investors injectable aesthetics is now priced by how long an effect lasts: Juvederm fell 6.6% while DAXXIFY holds RMB6,800.
099430.KQEOLSSRAMFLLY, MRK, PFE: 2026 Biotech M&A Patent Cliff Driver
Biotech M&A 2026 on track for best year since 2018. Patent cliffs (Keytruda 2028, Trulicity 2027) drive LLY/MRK/PFE acquisition urgency.
LLYMRKPFEPharma Tariffs: Buy LLY & AMGN, Sell PFE & MRK — Here's Why
Trump policies eroding Europe's pharma lead via tariffs favor US manufacturing-heavy Eli Lilly and Amgen, with strong growth and margins, while Pfizer and Merck's global chains invite cost squeezes. J&J and AbbVie sit in the middle with diversification. Rank: Buy LLY/AMGN, sell PFE/MRK.
LLYAMGNJNJPharma Tariffs: LLY and AMGN Win While PFE and MRK Face Margin Squeeze
Trump's pharma import tariffs shield U.S.-focused drugmakers like Eli Lilly and Amgen from cost hikes while pressuring import-reliant Pfizer and Merck. Analysis ranks six majors by exposure, highlighting financials and guidance. Domestic winners eye margin expansion amid onshoring push.
LLYAMGNJNJ
AbbVie Inc. company profile
Overview
AbbVie Inc. (NYSE:ABBV) is a pharmaceutical company that was spun off from Abbott Laboratories in 2013. The company emerged as an independent entity to focus exclusively on research-based pharmaceuticals, inheriting Abbott's established drug portfolio including the blockbuster immunology drug Humira. Since its inception, AbbVie has evolved from a company heavily dependent on a single product to a diversified pharmaceutical enterprise with a robust pipeline across multiple therapeutic areas. Today, AbbVie operates as one of the world's largest biopharmaceutical companies, with operations spanning immunology, oncology, neuroscience, and aesthetics.
Business
AbbVie operates in the global pharmaceutical industry, focusing on the discovery, development, manufacturing, and commercialization of prescription medications. The company's business is organized around four primary therapeutic areas: Immunology (approximately 50% of revenue): This segment represents AbbVie's largest revenue driver, centered around treatments for autoimmune diseases. The flagship products include Skyrizi (risankizumab), which treats moderate to severe plaque psoriasis and inflammatory bowel diseases like Crohn's disease and ulcerative colitis, and Rinvoq (upadacitinib), a JAK inhibitor used for rheumatoid arthritis, psoriatic arthritis, and other inflammatory conditions. These newer drugs are replacing the declining sales of Humira (adalimumab), which was once the world's best-selling drug but now faces biosimilar competition. Autoimmune diseases occur when the body's immune system mistakenly attacks healthy tissues, and these medications work by blocking specific pathways that drive inflammation. Oncology (approximately 12% of revenue): AbbVie's cancer treatment portfolio includes Imbruvica (ibrutinib) for blood cancers like chronic lymphocytic leukemia, and Venclexta (venetoclax), a BCL-2 inhibitor that helps cancer cells die naturally. The company is also developing antibody-drug conjugates (ADCs), which are targeted therapies that deliver chemotherapy directly to cancer cells while sparing healthy tissue. Neuroscience (approximately 17% of revenue): This segment includes treatments for psychiatric and neurological conditions. Key products include Vraylar (cariprazine) for bipolar disorder and schizophrenia, Botox Therapeutic for various neurological conditions including chronic migraines and muscle spasticity, and migraine medications Ubrelvy and Qulipta. The company recently acquired Cerevel Therapeutics to strengthen its neuroscience pipeline. Aesthetics (approximately 9% of revenue): This segment focuses on cosmetic treatments, primarily Botox Cosmetic for wrinkle reduction and various dermal fillers. These products are administered by healthcare providers to reduce signs of aging and enhance facial appearance.
Revenue model
AbbVie generates revenue primarily through direct product sales to wholesalers, distributors, and healthcare providers globally. The company operates under a traditional pharmaceutical business model where it invests heavily in research and development to create patented medications, then captures value through exclusive marketing rights during the patent protection period. The company's revenue streams include prescription drug sales in both developed and emerging markets, with pricing strategies that vary significantly by geography. In the United States, AbbVie typically commands premium pricing due to the value-based healthcare system, while international markets often involve government price negotiations and reference pricing mechanisms. Several factors influence AbbVie's profitability margins. Patent protection is crucial - drugs under patent exclusivity generate substantially higher margins than those facing generic or biosimilar competition, as evidenced by Humira's margin compression following biosimilar entry. Manufacturing scale provides cost advantages, particularly for complex biologics that require specialized production facilities. Regulatory approval timing affects revenue recognition, as delays can postpone market entry and revenue generation. Healthcare spending patterns impact demand, with economic downturns potentially reducing elective procedures in aesthetics while essential medications remain more resilient. Competition from innovative therapies can erode market share, requiring continuous investment in next-generation treatments. Pricing pressure from payers, government regulations, and public scrutiny of drug costs creates ongoing margin challenges, particularly in mature markets.
Competitive moat
AbbVie's competitive moat is moderately strong but faces ongoing challenges. The company's primary moat stems from its patent-protected intellectual property and regulatory barriers that prevent competitors from easily replicating its complex biologic drugs. Developing competing biologics requires substantial investment, lengthy clinical trials, and regulatory expertise, creating significant barriers to entry. The company has demonstrated strong research and development capabilities, successfully transitioning from Humira dependence to a diversified portfolio led by Skyrizi and Rinvoq. This innovation capacity, combined with deep relationships with healthcare providers and payers, provides some competitive protection. AbbVie's manufacturing expertise in complex biologics and its global commercial infrastructure represent additional competitive advantages. However, the moat faces notable vulnerabilities. The pharmaceutical industry's fundamental challenge is patent expiration - even the most successful drugs eventually lose exclusivity, as demonstrated by Humira's recent biosimilar competition. Regulatory risks can delay or prevent drug approvals, while clinical trial failures can eliminate years of investment. The company faces intense competition from other large pharmaceutical companies with similar capabilities and resources. Additionally, pricing pressure from government regulations and payer negotiations continues to intensify globally, potentially compressing margins even for patent-protected drugs. The rise of biosimilar competition and innovative drug delivery mechanisms from biotechnology companies poses ongoing threats to market share. While AbbVie has successfully navigated the Humira transition, the company must continuously innovate to maintain its competitive position, making its moat dependent on execution rather than structural advantages.
Risks & safety
AbbVie demonstrates a moderate margin of safety with some financial strengths offset by structural challenges: Liquidity and Solvency: • Cash and short-term investments: $5.2 billion (Q1 2025) • Current ratio: 0.76 (below 1.0 indicates potential short-term liquidity concerns) • Quick ratio: 0.64 (relatively low but manageable given strong cash flow generation) • Debt-to-equity ratio: 49.2 (high leverage but typical for mature pharmaceutical companies) Valuation Metrics: • Price-to-earnings ratio: 72.0 (elevated, reflecting growth expectations) • EV/EBITDA: 29.1 (high multiple suggesting premium valuation) • Free cash flow: $1.4 billion (Q1 2025), demonstrating strong cash generation capability Other Considerations: • Strong operational cash flow generation provides financial flexibility • Diversified revenue base reduces single-product dependency risk • Patent cliff risks require continuous R&D investment and successful drug launches • High debt levels manageable due to predictable cash flows but limit financial flexibility
Recent development
Over the past few years, AbbVie has executed a strategic transformation from a company dependent on Humira to a diversified pharmaceutical enterprise. The most significant development has been the successful launch and rapid growth of Skyrizi and Rinvoq, which have become the company's new growth engines. These immunology drugs have demonstrated exceptional market uptake, with combined sales reaching over $5 billion in recent quarters and projected to generate nearly $24 billion in 2025. The company has significantly expanded its neuroscience portfolio through the acquisition of Cerevel Therapeutics, adding promising assets in psychiatry and neurodegeneration. Key neuroscience developments include the advancement of tavapadon for Parkinson's disease and the launch of Vyalev for advanced Parkinson's patients. AbbVie has also strengthened its migraine franchise with Ubrelvy and Qulipta, establishing a comprehensive neurological portfolio. In oncology, AbbVie has focused on developing antibody-drug conjugates (ADCs) including Teliso-V for non-small cell lung cancer, which has shown promising clinical results. The company has also advanced Epkinly for blood cancers and continues to expand Venclexta's indications. The aesthetics business has faced market headwinds but AbbVie is preparing for recovery with the development of BoNT/E, a novel botulinum toxin that could differentiate its aesthetic offerings. The company recently entered the obesity market through a partnership with Gubra, focusing on amylin analog treatments that could address unmet needs in weight management. AbbVie has also pursued an aggressive business development strategy, signing over 20 early-stage deals across its core therapeutic areas to strengthen its pipeline for the next decade. This includes investments in multispecific antibodies, novel drug delivery mechanisms, and emerging therapeutic modalities.
ABBV company profile · for informational purposes only — not investment advice.
Track ABBV with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free